Guanfacine IR to XR Conversion
Convert guanfacine 2 mg IR twice daily (total 4 mg/day) to guanfacine XR 4 mg once daily.
Conversion Rationale
The immediate-release and extended-release formulations of guanfacine are not interchangeable on a milligram-for-milligram basis due to different pharmacokinetic profiles 1, 2. However, for total daily dose conversion, the approach is straightforward:
- Calculate total daily IR dose: 2 mg BID = 4 mg/day total
- Convert to equivalent XR dose: 4 mg XR once daily
- Timing: Administer XR formulation once daily, preferably at bedtime to minimize somnolence 3
Key Pharmacokinetic Differences
While the formulations differ in their release profiles, research demonstrates that 3 mg/day IR guanfacine produces similar 24-hour plasma levels to 4 mg/day ER guanfacine 4. This suggests the XR formulation may require slightly higher total daily doses to achieve equivalent exposure, but when converting from established IR therapy, matching the total daily dose (4 mg) is the appropriate starting point.
The extended-release formulation provides:
- Once-daily dosing with sustained plasma levels 5
- "Around-the-clock" symptom control 3
- Potentially reduced peak-related side effects
Dosing Guidelines
Guanfacine XR is available in 1,2,3, and 4 mg tablets 3. The recommended approach:
- Weight-based dosing: Target 0.05-0.12 mg/kg/day 3
- Maximum approved dose: 4 mg/day in most guidelines 3, 6
- Higher doses: Some studies have evaluated doses up to 6-9 mg/day in adolescents, but these exceed FDA-approved dosing and require careful monitoring 7, 8
Critical Safety Considerations
Cardiovascular Monitoring
Monitor closely for:
- Hypotension and bradycardia (most common cardiovascular effects) 3, 6
- Baseline and periodic blood pressure and heart rate measurements required
- Dose-dependent decreases in BP and HR expected 7
Common Adverse Effects
- Somnolence (most frequent, typically mild-to-moderate) 3, 9
- Fatigue, headache, irritability 3
- Dry mouth, dizziness, abdominal pain 6
Critical Warning: Discontinuation
Never abruptly discontinue guanfacine 6, 10. Rebound hypertension can occur, though it is:
- Less frequent than with clonidine 10
- Delayed 2-4 days after discontinuation 10
- Requires gradual taper if stopping therapy 6
Conversion Protocol
- Switch directly from 2 mg IR BID to 4 mg XR once daily at bedtime
- Monitor vital signs within first week: BP and HR sitting and standing
- Assess tolerability for somnolence, particularly in first 2-4 weeks 3, 9
- Expect therapeutic effect within 2-4 weeks (slower onset than stimulants) 3
Special Populations
- Hepatic/renal impairment: Dose reduction may be needed; guanfacine is primarily renally excreted 3
- CYP3A4 interactions: Guanfacine is metabolized via CYP3A4; adjust for strong inhibitors/inducers 3
- Elderly patients: Start with lower doses (1-2 mg) due to increased sensitivity 11
Clinical Context
Guanfacine XR provides medium effect sizes for ADHD core symptoms, smaller than stimulants but with benefits including 3:
- Non-controlled substance status
- 24-hour symptom coverage
- Potential benefits for comorbid tic disorders, oppositional symptoms, and sleep disturbances 3
The 4 mg total daily dose falls within the therapeutic range and should provide equivalent efficacy to the current IR regimen with improved convenience and potentially better tolerability due to more stable plasma levels throughout the day.